3 Stocks Driving The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 60 points (0.4%) at 16,517 as of Tuesday, April 1, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,859 issues advancing vs. 1,154 declining with 141 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.4%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 2.2%, Alexion Pharmaceuticals ( ALXN), up 1.9%, Actavis ( ACT), up 1.8%, Valeant Pharmaceuticals International ( VRX), up 1.4% and AstraZeneca ( AZN), up 0.4%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $1.29 (1.1%) to $124.63 on average volume. Thus far, 1.4 million shares of Amgen exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $123.51-$125.90 after having opened the day at $123.67 as compared to the previous trading day's close of $123.34.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $91.0 billion and is part of the health care sector. Shares are up 8.1% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Celgene Corporation ( CELG) is up $5.95 (4.3%) to $145.55 on average volume. Thus far, 2.5 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $142.00-$147.17 after having opened the day at $142.00 as compared to the previous trading day's close of $139.60.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene Corporation has a market cap of $56.6 billion and is part of the health care sector. Shares are down 17.4% year-to-date as of the close of trading on Monday. Currently there are 23 analysts who rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $2.22 (3.1%) to $73.08 on heavy volume. Thus far, 10.6 million shares of Gilead exchanged hands as compared to its average daily volume of 13.0 million shares. The stock has ranged in price between $72.14-$73.88 after having opened the day at $73.34 as compared to the previous trading day's close of $70.86.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $105.4 billion and is part of the health care sector. Shares are down 5.7% year-to-date as of the close of trading on Monday. Currently there are 19 analysts who rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

The Shifting Price Action Continued Today

The Shifting Price Action Continued Today

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)